• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bellerophon nabs $23m in private placement

September 27, 2017 By Sarah Faulkner

Bellerophon TherapeuticsBellerophon Therapeutics (NSDQ:BLPH) said today that it inked a deal with new and existing investors to raise $23.4 million in a private placement of common stocks and warrants.

The financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners, supported by existing investors like New Mountain Capital and Linde North America, the Warren, N.J.-based company said.

According to the deal, Bellerophon will sell 19.4 million shares of common stock and warrants to purchase 19.4 million shares of common stock for aggregate gross proceeds of $23.4 million. The warrants will have an exercise price of $1.242 per share and will be exercisable after six months, expiring five years from the date of issuance.

The sales of these securities is slated to take place on Sept. 29.

The company said it plans to use the funds to support the continued development of its INOpulse platform, including Phase III trials in pulmonary arterial hypertension and Phase II trials in pulmonary hypertension associated with interstitial lung disease and chronic obstructive pulmonary disease.

Earlier this month, Bellerophon touted data from a Phase II trial of its INOpulse therapy in patients with pulmonary hypertension associated with COPD.

The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity.

The data showed a statistically significant increase in blood vessel volume compared to baseline and a statistically significant increase in six-minute walking distance at 2 weeks and 4 weeks compared to baseline.

The study also showed a meaningful decrease in systolic pulmonary arterial pressure after 4 weeks. Bellerophon’s therapy was well tolerated, the company reported, with no related safety concerns.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: Bellerophon Therapeutics

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS